Laidlaw Starts F-Star Therapeutics Inc. (FSTX) at Buy
- Wall Street opens flat as big banks kick off earnings season
- Coinbase (COIN) direct listing IPO reference price set at $250
- Federal Bureau of Prisons says Ponzi schemer Bernard Madoff has passed away
Laidlaw analyst Yale Jen initiates coverage on F-Star Therapeutics Inc. (NASDAQ: FSTX) with a Buy rating and a price target of $32.00.
Shares of F-Star Therapeutics Inc. closed at $11.59 yesterday.
You May Also Be Interested In
- UPDATE: KeyBanc Starts Denbury Inc. (DEN) at Overweight as the Only E&P with Negative Carbon Footprint
- UPDATE: CIBC Starts Gatos Silver (GATO) at Outperformer
- Roth Capital Starts Ideanomics Inc. (IDEX) at Buy, 'Portfolio Effect Lifts Traction in Commercial EVs'